To include your compound in the COVID-19 Resource Center, submit it here.

Introgen on its own

After inheriting a gaggle of gene therapy assets and collaborators when it was formed in 1998, Aventis S.A. is unwinding its gene therapy portfolio, in the process leaving Introgen Therapeutics Inc. on its own to complete clinical development of its gene therapy to treat cancer.

Rhone-Poulenc Rorer Inc., now AVE, created its RPR Gencell division in November 1994 to develop gene therapy technology and products through a network of deals with companies and institutions, including INGN,

Read the full 758 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers